NCT06383858Recruiting
The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center
The Project of Gestational Hypertension and Preeclampsia Screening and Prevention
Source: ClinicalTrials.gov · Last updated 19 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50000 (estimated)
- First submitted
- 14 Apr 2024
- Start date
- 1 Aug 2023
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Diseases
- High blood pressure
- NCT number
- NCT06383858
What you commit to
- Study type: Observational
- Planned participants: 50000
- From 1 Aug 2023 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- 3\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers;
Other
- 1\) Severe fetal malformation or abnormality (no fetal heartbeat);
- 2\) Those who regularly use aspirin before joining the group;
- 4\) Unable to obtain follow-up and delivery information.
Who the study is looking for
- 1\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019);
- 2\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1/PLGF in the second and third trimesters to assess the risk of preeclampsia.
- 3\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form.
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FANG HE Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.